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Abstract
 
We screened 29 strains of 
 
Neisseria gonorrhoeae
 
 and found 16/21 strains that resisted killing by
normal human serum and 0/8 serum sensitive strains that bound the complement regulator,
C4b-binding protein (C4bp). Microbial surface–bound C4bp demonstrated cofactor activity.
We constructed gonococcal strains with hybrid porin (Por) molecules derived from each of the
major serogroups (Por1A and Por1B) of 
 
N. gonorrhoeae
 
, and showed that the loop 1 of Por1A is
required for C4bp binding. Por1B loops 5 and 7 of serum-resistant gonococci together formed
a negatively charged C4bp-binding domain. C4bp–Por1B interactions were ionic in nature
(inhibited by high salt or by heparin), whereas the C4bp–Por1A bond was hydrophobic. Only
 
recombinant C4bp mutant molecules containing the NH
 
2
 
-terminal 
 
a
 
-chain short consensus
repeat (SCR1) bound to both Por1A and Por1B gonococci, suggesting that SCR1 contained
Por binding sites. C4bp 
 
a
 
-chain monomers did not bind gonococci, indicating that the poly-
meric form of C4bp was required for binding. Using fAb fragments against C4bp SCR1, C4bp
binding to Por1A and Por1B strains was inhibited in a complement-dependent serum bacteri-
cidal assay. This resulted in complete killing of these otherwise fully serum resistant strains in
only 10% normal serum, underscoring the importance of C4bp in mediating gonococcal se-
rum resistance.
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Introduction
 
Neisseria gonorrhoeae
 
 is one of two bacterial pathogens in-
volved in the majority of cases of sexually transmitted geni-
 
tal infection and pelvic inflammatory disease (PID);
 
1
 
 the
other is 
 
Chlamydia trachomatis
 
. Gonococci that cause symp-
tomatic local inflammation (PID) usually are sensitive to
killing by nonimmune normal human serum (NHS) in
vitro (1). Complement component C3 is present in func-
tional amounts at the cervical level (2, 3), is synthesized in
the endometrial glandular epithelium (4, 5), and binds to
gonococci in vivo (6). Serum-sensitive (SS) gonococci can
abrogate killing by NHS by adding sialic acid to their lipo-
oligosaccharide (LOS [7–11]), which permits direct binding
of the complement regulatory protein factor H to sialylated
LOS (12). This is termed unstable serum resistance (SR). In
vivo, gonococci appear to be heterogeneously sialylated (6,
13). Disseminated bloodstream infection with gonococci
(DGI) often occurs in the absence of local genital inflamma-
tion and is caused predominantly by gonococci that resist
killing by NHS independent of sialylation, termed stable se-
rum resistance (14). These isolates sometimes lack the LOS
acceptor site for sialic acid (15), or may not completely sial-
ylate LOS for reasons that remain unclear. Commonly they
also express the gonococcal major outer membrane protein
serotype porin (Por)1A (16, 17). Gonococcal Por comprises
60% of the outer membrane protein content (18). Por is a
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34–35-kD protein comprising 8 transmembrane loops (16
membrane spanning segments) whose native configuration
is a homogenous trimer that functions as a selective anion
channel (18, 19). Por is an allelic protein consisting of two
main isoforms, Por1A and Por1B (17, 20). There is moder-
ate antigenic variation between the isoforms, which subdi-
vides them into serotypes or serovars (21–23). Por1A gono-
cocci frequently cause disseminated disease, whereas Por1B
strains usually cause local urogenital disease and PID in
women (16, 17, 20). We have recently shown that Por1A
isolates resist killing by directly binding factor H, a regulator
of the alternative pathway of complement, to the surface
exposed loop 5 of Por1A (24).
Although the alternative pathway is important in C3
deposition on the gonococcal surface, the classical pathway
of complement is required to initiate this deposition and
resultant killing (25). A key soluble phase classical pathway
regulatory protein is C4b-binding protein (C4bp), which
is present in human plasma at concentrations of 200–250
 
m
 
g/ml. C4bp is a cofactor in factor I–mediated cleavage of
C4b to C4d, and accelerates dissociation of C2a from the
classical pathway C3 convertase (C4b, 2a), thereby down-
regulating the classical pathway (26–30). C4bp (
 
M
 
r
 
 
 
5
 
 570
kD) is composed of seven identical 70-kD subunits (
 
a
 
-
chains) linked by disulfide bridges (30, 31). When visual-
ized by electron microscopy, it appears as a spider-like
structure with seven elongated tentacles (
 
a
 
-chains) ex-
tending from a central, ring-like core (32, 33). The NH
 
2
 
-
terminal 491 (of a total of 549) residues of each 
 
a
 
-chain
are organized into eight short consensus repeat (SCR) do-
mains, and each SCR is comprised of 
 
z
 
60 amino acids. A
patch of positively charged residues at the interface be-
tween the first and second NH
 
2
 
-terminal SCRs plays an
important role in the interaction between C4bp and C4b
as well as heparin (34). C4bp also contains a 45-kD sub-
unit (
 
b
 
-chain), organized into three SCRs, which is at-
tached to the central core region of the molecule by a di-
sulfide bond (35). Three isoforms with different subunit
compositions have been identified in human plasma; the
major isoform is comprised of seven 
 
a
 
-chains and one
 
b
 
-chain (
 
a
 
7
 
b
 
1); the remaining isoforms are 
 
a
 
7
 
b
 
0 and
 
a
 
6
 
b
 
1 (36).
Many isolates of
 
 Streptococcus pyogenes
 
 have been reported
to bind C4bp, which may contribute to pathogenicity (37).
Binding of C4bp occurs through the NH
 
2
 
-terminal highly
variable region of several members of the M protein family
present in this species (38). In addition, C4bp binding has
been demonstrated to all clinical isolates of 
 
Bordetella pertus-
sis
 
 expressing the filamentous hemagglutinin (39). Because
the classical pathway is crucial in initiating complement
deposition on gonococci (25), regulation of this pathway
could provide a very efficient means for the bacteria to
evade the bactericidal action of serum at an early stage of
complement activation. In this work, we detail the interac-
tions between C4bp and gonococcal Por, and demonstrate
the function of C4bp in mediating stable SR (SR not me-
diated by LOS sialylation).
 
Materials and Methods
 
Bacterial Strains and Plasmids.
 
29 strains of 
 
N. gonorrhoeae
 
 were
screened for binding to C4bp; these are listed in Table I. Strain
FA6616, containing the MS11 Por molecule reintroduced into
an MS11 background using plasmid pUNCH61 (40), was used in
this study, and for convenience will be referred to as MS11 here-
after. Bacteria grown on chocolate agar supplemented with Isovi-
talex equivalent in 5% CO
 
2
 
 for 10 to 11 h (41) were suspended in
HBSS containing 0.15 mM CaCl
 
2
 
 and 1 mM MgCl
 
2
 
 (HBSS
 
2
 
1
 
)
in C4bp binding assays. Alternatively, bacteria were harvested
from chocolate agar plates after overnight growth and grown in
gonococcal liquid media (41). Results of C4bp binding were
equivalent when strains were grown in either media. Plasmids
 
Table I.
 
C4bp Binding and Phenotype of 29 Strains of
Neisseria gonorrhoeae
 
Strain (reference) Phenotype C4bp binding
Por1A strains
15253 (78, 79) SR
 
1
 
401082 (24) SR
 
1
 
339063 (24) SR
 
1
 
DGI isolate 1 (14) SR
 
1
 
179008 (24) SR
 
1
 
FA19 (80, 81) SR
 
1
 
442089 (24) SR
 
1
 
273043 (24) SR
 
1
 
UU1 (46, 47) SS
 
2
 
374073 (24) SR
 
2
 
DGI isolate 56 (this study) SR
 
2
 
Por1B strains
FA1090 (82) SR
 
1
 
156001 (24) SR
 
1
 
1291 (83) SR
 
1
 
BMC-1 (84) SR
 
1
 
FA6616
 
*
 
 (40) SR
 
1
 
WG (14) SR
 
1
 
422083 (24) SR
 
2
 
252 (24) SR
 
2
 
336062 (24) SR
 
2
 
DGI isolate 40 (14) SR
 
1
 
DGI isolate 17 (14) SR
 
1
 
398079 (24) SS
 
2
 
256036 (24) SS
 
2
 
255034 (24) SS
 
2
 
F62 (85) SS
 
2
 
24-1 (61) SS
 
2
 
Pgh 3-2 (46, 47) SS
 
2
 
150002 (24) SS
 
2
 
*
 
Referred to as MS11 in this study. 
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pUNCH61 and pUNCH62 contained the 
 
por1B
 
 and 
 
por1A
 
genes of strains MS11 and FA19, respectively, plus 
 
z
 
1 kB of
gonococcal DNA 3
 
9
 
 to the 
 
por
 
 gene, respectively, containing a
chloramphenicol-resistance marker (Cm
 
R
 
 [40, 42]). Strains MS11
and FA19 are resistant to killing (SR) by 33% nonimmune NHS.
pUNCH61 and pUNCH62 were each used to transform the SS
strain F62 to replace F62 Por with either MS11 Por (F62
 
PorMS11
 
)
or FA19 Por (F62
 
PorFA19
 
), respectively. In addition to replacing
Por completely, transformation with pUNCH61 resulted in hy-
brids F62
 
loop1
 
MS11
 
loop2–8
 
, and F62
 
loop1–4
 
MS11
 
loop5–8
 
 (see Fig. 4),
and transformation of F62 with pUNCH62 yielded hybrids
F62
 
loop1
 
FA19
 
loop2–8
 
 and F62
 
loop1–4
 
FA19
 
loop5–8
 
 (see Fig. 3). Because
C4bp binding studies with these MS11/F62 hybrids suggested
that the C4bp binding region in MS11 Por was contained in the
COOH
 
-
 
terminal half of the Por molecule (see Results), we then
constructed hybrid MS11
 
loop1
 
F62
 
loop2–7
 
MS11
 
loop8 
 
by replacing the
 
BbsI-BsgI
 
 fragment of MS11 Por encompassing loops 2 through 7
in pUNCH61 with the corresponding 
 
BbsI-BsgI
 
 fragment of F62
 
Por. Using this plasmid, designated pBUMC1, we constructed
hybrids that were mutated at loops 5, 6, or 7 individually or in
combination, using either overlap extension PCR for loops 5 and
6, or site-directed mutagenesis for loop 7 (see below: Por mu-
tagenesis). The amino acid sequences of the putative exposed re-
gions of Por loops 5, 6, and 7 of F62 and MS11 are indicated in
Table II; variations in sequence are indicated in bold type. The
net charge of the surface exposed loop regions was calculated by
assigning 
 
11 for arginine (R) and lysine (K), and 10.5 for histi-
dine (H), and –1 for aspartic acid (D) and glutamic acid (E), as
described previously (43).
Por Mutagenesis. We used overlap extension PCR to replace
MS11 loop 5 or 6 with F62 loops 5 or 6, respectively, and vice
versa (44). To construct each mutation, we performed two sepa-
rate PCR reactions with the primer pairs listed in Table III. De-
naturation for this PCR was carried out at 948C for 1 min, an-
nealing temperatures varied between 58 and 618C, and extension
was performed at 728C for 1 min. PCR products were gel puri-
fied using the GeneClean kit (Bio 101). The products of gel puri-
fication were then subjected to a second PCR reaction using
primers PorI and PorII, followed by gel purification of the PCR
product. This PCR reaction consisted of 10 cycles of overlap
(948C for 30 s followed by 728C for 2 min) followed by 15 exten-
sion cycles of denaturation at 948C for 1 min, annealing at 588C
for 1 min, and extension at 728C for 1 min. The products ob-
tained from this PCR reaction were then digested with BbsI and
BsgI, and the resultant z800-bp fragment gel purified and cloned
into the BbsI-BsgI site in pUNCH61 or pBUMC1. Loop 7 muta-
tions were made using pUNCH61 (to replace MS11 loop 7 with
F62 loop 7) or the reverse in pBUMC1 (to replace F62 loop 7
with MS11 loop 7), using the QuikChange™ site-directed mu-
tagenesis kit (Stratagene) according to the manufacturer’s instruc-
tions. In these reactions, primer 59-AGG CAC TGT TGA TAG
TGC AGA CCA CGA CAA TAC-39 and its complimentary an-
tisense counterpart were used to exchange MS11 loop 7 with F62
loop 7, and 59-AGG CAC TGT TCA TAG TGC AGA CTA
CGA CAA TAC-39 and its antisense counterpart were used to
exchange F62 loop 7 with MS11 loop 7. Gonococcal transfor-
mants were screened using mAb 1F5 (21; see below) that recog-
nizes MS11 Por loop 1 (42), but does not react with F62. To en-
Table II. Comparison of Putative Exposed Sequences of Por Loops 
5, 6, and 7 of Strains MS11 and F62
Por
loop Strain
Sequence of putative
surface-exposed region*
Net
charge‡
Loop 5 MS11 RYGEGTKKIE-YEHQVYSIPSLFVEKL 10.5
F62 RYGEGTKKMEGY---AYNIPSLFVEKL 11
Loop 6 MS11 DAKLYQNQLVRDNSHNSQTE 20.5
F62 DAKLYGTW--RANSHNSQTE 10.5
Loop 7 MS11 VDSADHDNTYDQV 23.5
F62 VHSADYDNTYDQV 22.5
*Variations in sequence are underlined.
‡Net charge calculated by assigning 21 for D and E, 11 for R and
K, and 10.5 for H (reference 43).
Table III. Primer Pairs Used for Constructing MS11-F62 Hybrid Por Molecules Using Overlap Extension PCR
Mutation Primer sequence (59®39)
F625 to MS115 GGGATACTATAAACTTGATGTTCGTATTCGATTTTTTTAGTG/PorI*
CGAATACGAACATCAAGTTTATAGTATCCCCAGCCTGTTTGT/PorII*
F626 to MS116 TCACGCACTAATTGATTTTGATACAATTTGGCATCTTGTTG/PorI
TTGTATCAAAATCAATTAGTGCGTGATAATTCGCACAACTCTCAA/PorII
MS115 to F625 AAACTGGGGATATTATATGCATATCCTTCCATTTTTTTAGTGCCTTCGCCG/PorI
AAAAATGGAAGGATATGCATATAATATCCCCAGTTTGTTTGTTTGTTGAAAA/PorII
MS116 to F626 GCACGCCATGTTCCATACAATTTGGCATCTTGTTGTTGTG/PorI
CACAACAACAAGATGCCAAATTGTATGGAACATGGCGTGC/PorII
*PorI (59-GGCGAATTCCGGCCTGCTTAAATTTCTTA-39) and PorII (59-GCGAAGCTTATTAGAATTTGTGGCGCAG-39) have been
described previously (reference 86).284 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
sure that the desired mutation had been obtained in F62, entire
por genes of mAb 1F5-positive clones were amplified using prim-
ers PorI and PorII, and DNA sequencing was performed at the
DNA core facility at Boston University School of Medicine using
an Applied Biosystems automated sequencer.
In an effort to obtain a strain containing loop 1 of FA19 and
loops 2–8 of F62, we cloned the chloramphenicol-resistance
marker into the HincII site of gonococcal DNA 59 to the FA19
por1A gene in pUNCH 30 (45), and used this plasmid, desig-
nated pBUMC2, to transform F62. Attempts to create a hybrid
Por molecule containing the NH2 terminus of the FA19 Por and
the COOH terminus of F62 Por were not successful; therefore,
we attempted to construct a hybrid Por molecule that contained
loop 1 from strain FA19 and loops 2–8 from another gonococcal
strain, UU1 (46, 47). UU1 is a Por1A strain that is SS and does
not bind C4bp. We introduced a SpeI site 2 bp 39 to the UU1 por
gene by PCR using PorI as the forward primer and 59-GCG
ACT AGT ATT AGA ATT TGT GGC GCAG-39 as the re-
verse primer. Then, using the QuikChange™ site-directed mu-
tagenesis kit (Stratagene), a SpeI site was similarly introduced 39
to the FA19 por1A gene in pUNCH62 using primer 59-GAC
AGA CTA GTT GTT GAT ACC GAT-39 and its complemen-
tary primer. A new construct was made by ligating the BbsI-SpeI
fragment of UU1 into pUNCH62, which had been predigested
with the same enzymes. The resultant plasmid, pBUMC3, that
contained hybrid Por molecule FA19loop1UU1loop2–8 was used to
attempt transformation of strains F62 and UU1 (see Results:
C4bp Binding Region in Por1A).
Sera and Complement Reagents. Nonimmune NHS was ob-
tained from 10 healthy volunteers with no prior history of neis-
serial infection. Sera were aliquoted and stored at 2708C until
further use. In some experiments, NHS was incubated at 568C
for 30 min to yield heat-inactivated serum (HIS). NHS was ad-
sorbed against glutaraldehyde-fixed bacteria (strain F62PorMS11) on
ice to deplete serum of bacteria-specific Ig, as described previ-
ously (41), and used as an antibody-free complement source in
certain experiments (see Results: Enhanced IgM Binding to
F62PorMS11: Por influences IgM Binding to Gonococci). Purified
C4b was obtained from Advanced Research Technologies. C4bp
that was either complexed to or devoid of protein S (a compo-
nent of the protein C anticoagulation system) was purified from
human plasma using previously described methods (48).
Recombinant C4bp Mutant Proteins. Recombinant human
C4bp and seven polymeric rC4bp mutant molecules lacking indi-
vidual SCRs were constructed by an overlapping PCR technique
that used as a template full-length cDNA coding for the a-chain
of human C4bp (49) cloned in vector pcDNA3 (Invitrogen). The
amino acids deleted (represented as deletions of SCRs 1 to 7 de-
leted sequentially) in each construct and sequences of primers
used are listed in Table IV. The final PCR product was cloned
into HindII and NotI sites in vector pcDNA3 and used as the
transfecting construct. Nucleotide sequences of all mutations
were determined by automated DNA sequencing (PerkinElmer).
Human kidney 293 cells (American Type Culture Collection
catalog no. 1573-CRL) were transfected with individual C4bp
constructs, and the expressed proteins, with the exception of
rC4bpDSCR1, were purified by affinity chromatography using
mAb 104 (specific for C4bp SCR1) as described previously (50).
rC4bpDSCR1 was affinity purified using mAb 67 (specific for
C4bp SCR 4; reference 51).
C4bp a-chain monomers containing all eight SCRs were con-
structed by introducing the STOP codon after SCR 8 using
primer 59-CCC AAG TGT GAG TGG TAG ACC CCC GAA
GGC TGT-39 (stop codon indicated in bold).
Ab. Transformants were screened using serotyping mAbs
against gonococcal Por (21). These included mAb 2F12 (specific
for FA19 Por loop 1), 9D2 (central region of FA19 Por), 1F5
(MS11 Por loop 1), and 3C8 (loop 5 of MS11 Por). These mAbs
were used in colony blotting experiments or in whole cell ELISA
at a dilution of 1 mg/ml in PBS-0.05% Tween 20.
Anti-C4bp mAb (Quidel Corp.) was used in flow cytometry
experiments (see below) at a concentration of 20 mg/ml in
HBSS21. In some experiments, a sheep polyclonal Ab against hu-
man C4bp (Biodesign International) was used in flow cytometry
experiments at a dilution of 1:50 in HBSS21. mAbs specific for
C4c and C4d were purchased from Quidel Corp., and used in
flow cytometry experiments at a dilution of 20 mg/ml in
HBSS21. C4c and C4d are the fragments of C4b generated when
the enzyme factor I acts together with its cofactor C4bp to cleave
C4b. C3 bound to bacteria was detected using an IgG fraction of
goat anti–human C3 (Organon Teknika-Cappel) at a concentra-
tion of 100 mg/ml. C5b-9 on the bacterial surface was detected
by flow cytometry using an IgG fraction of rabbit anti–human
SC5b-9 neoantigen (Advanced Research Technologies) at a 1:50
dilution in HBSS21. To identify the region in C4bp that bound
gonococcal Por, we used five mAbs directed against C4bp SCR 1
to 2 (mAb 104, mAb 102, mAb 96, mAb 92, and mAb 70) and
mAb 67 (specific for SCR 4 of the a-chain of C4bp; reference
51), in experiments to attempt to inhibit binding of C4bp to the
bacterial surface. The functional effects of abrogating C4bp bind-
Table IV. Primers Used for Construction of Recombinant Human C4bp Deletion Mutant Molecules
rC4bp protein Amino acids deleted Sense primer (59®39)*
rC4bp DSCR1 N1 to Y62 CCT GCT GTT CTT GGC AAA CGA TGC AGA CAC
rC4bp DSCR2 K63 to I124 ACC TTC TGT ATC TAC GTC AAG TGT AAG CCT
rC4bp DSCR3 V125 to K188 CCA CAA TGT GAA ATT ATC ACC TGT CGC AAG
rC4bp DSCR4 K188 to N249 CCT CCT ACC TGT GAA AAT AGT TGT ATT AAT
rC4bp DSCR5 N 249 to A314 CCT GCT TGT GAG CCC TTA TGT TGC CCT GAA
rC4bp DSCR6 A314 to G375 TAC CAA GGA TGT GAG GAC ATT TGC AAT TTT
rC4bp DSCR7 D376 to K433 ACA CCA TCA TGT GGA GCT CTG TGC CGG AAA
*The sense primer listed above was used in conjunction with primer T7, and its complimentary antisense counterpart was used with primer Sp6 in-
cluded in the polylinker sequence of the vector.285 Ram et al.
ing to the bacterial surface were studied by using fAb fragments
of mAb 104 to avoid confounding by possible Fc related effects of
the inhibiting Ab; fAb fragments of mAb 67 (specific for C4bp
SCR 4), shown not to influence C4bp binding to bacteria, were
used as controls. fAb fragments were generated from mAb 104 by
digestion with immobilized papain using a kit (Pierce Chemical
Co.) according to the manufacturer’s instructions. We observed
that papain digestion of mAb 67 did not yield the desired z50-
kD fAb fragment, but instead a 110-kD (possibly F[ab9]2) frag-
ment. However, digestion with immobilized pepsin yielded 50-
kD fragments that retained the capacity to bind C4bp by ELISA
(see below).
Flow Cytometry. Flow cytometry was used to quantify IgM,
C4bp, C4c, C4d, C3, and C5b-9 binding to the bacterial surface,
using methods described previously (12). In brief, 108 bacteria
suspended in HBSS21 were incubated either with NHS, purified
C4bp, or rC4bp deletion mutant molecules (quantity specified in
each experiment, final volume of reaction mixture 100 ml), fol-
lowed by detection of the indicated component using the speci-
fied primary and appropriate FITC-labeled secondary conjugate
(Sigma-Aldrich). In some experiments, inhibition of C4bp bind-
ing was attempted using high salt conditions, heparin, pure C4b,
anti-C4bp mAbs, or their fAb fragments (see above). Conditions
are specified for each experiment.
Bactericidal Testing. Serum bactericidal testing was performed
as described previously (41). In some experiments, C4bp binding
to the bacterial surface was abrogated using 25 mg fAb 104. This
represents an z70-fold molar excess of fAb 104 over C4bp in a
bactericidal assay using 10% NHS. In bactericidal experiments to
demonstrate that enhanced Ab binding was responsible for the se-
rum sensitive phenotype of F62PorMS11, organisms were incubated
with either 15 ml HIS (antibody source) or buffer (control), and
NHS adsorbed against glutaraldehyde-fixed F62PorMS11 was used
as a source of complement. The final volume of the bactericidal
reaction mixture in every experiment was maintained at 150 ml.
ELISA. To determine whether fAb fragments of mAb 67 re-
tained the ability to bind C4bp, we coated ELISA plates with ei-
ther 10 mg/ml mAb 67 or the derived fAb fragment in bicarbon-
ate buffer pH 9.6 for 2 h at 378C, followed by blocking with 1%
porcine gelatin (Sigma-Aldrich) for 30 min at 378C. Plates were
then washed twice with PBS-0.05% Tween 20, and cell culture
supernatant containing rC4bp was applied to each well for 1 h at
378C. After washing with PBS-Tween, bound C4bp was de-
tected using a sheep polyclonal anti-C4bp (Biodesign) and alka-
line phosphatase–conjugated anti–sheep IgG (Sigma-Aldrich).
The OD410nm obtained with binding of rC4bp to the fAb frag-
ment was compared with the OD410nm obtained with rC4bp
binding to the intact mAb.
Results
C4bp Binding Correlates with Serum Resistance
We screened 29 clinical and laboratory gonococcal iso-
lates (Table I) for C4bp binding using flow cytometry.
Strains were incubated with 10% NHS for 30 min, fol-
lowed by detection with an anti-C4bp mAb. The geomet-
ric mean fluorescence intensity of C4bp binding did not
differ among strains that bound C4bp, when tested under
similar assay conditions (representative positive and nega-
tive tracings are shown in Fig. 2 by F62PorFA19 and
F62PorF62, respectively). Resistance of each of the 29 strains
to killing by 10% NHS is indicated as phenotype in Table
I. 11 strains belonged to the Por1A serogroup; the remain-
ing 18 were Por1B. 10 of 11 Por1A strains were resistant to
killing by 10% NHS (SR). 8 of the 10 SR Por1A strains
bound C4bp; the only SS Por1A strain that was tested did
not bind C4bp. 11 of the 18 Por1B strains were SR, and 8
of these strains bound C4bp; no SS Por1B strains bound
C4bp. A strong correlation was observed between C4bp
binding and a SR phenotype (P , 0.0001 by Fisher’s exact
test).
We noted that all Por1B strains that bound C4bp belonged
to closely related serovars, and most bound the serotyping
mAb 3C8 (21) that is specific for loop 5 of certain Por1B
strains (52). This suggested the possibility that the central re-
gion of Por1B might be important in C4bp binding.
C4bp Binds Directly to Gonococci; Protein S Does Not Influence 
C4bp Binding
The major isoform of C4bp found in blood is seven
a-chains and one b-chain (a7b1), and virtually all C4bp
(a7b1) is complexed with protein S, a component of the
protein C anticoagulation system (48). To consider a possi-
ble effect of protein S in influencing C4bp binding to
gonococci, we compared the binding of 2.5 mg of pure
C4bp free of protein S and an equivalent amount of C4bp
coupled to protein S to strains FA19 (Por1A) and MS11
(Por1B). The amount of C4bp bound to the two strains
under each condition of incubation was similar (data not
shown), thereby suggesting that C4bp binding is not influ-
enced by protein S.
C4bp Bound to Gonococci Has Cofactor Function
C4bp regulates classical complement pathway activation
by serving as a cofactor in the inactivation of C4b by factor
I, and yields the C4 fragments C4d (which remains bound
to the bacterial surface) and C4c (released into solution).
Cofactor function of C4bp was assessed using mAbs di-
rected against C4c and C4d. mAb against C4d is specific
for the parent molecule C4b as well as the fragment C4d,
whereas mAb against C4c recognizes C4b and C4c, but
not C4d. Therefore, cofactor activity will not alter the
amount of C4 measured on the bacterial surface by the
mAb against C4d, but will decrease the amount of C4
bound to the organism measured by mAb against C4c, re-
sulting in a higher C4d/C4c ratio (53). We measured C4c
and C4d on strains incubated in 20% NHS for 30 min at
378C. We used strain F62 (SS, Por1B, does not bind
C4bp), FA19 (SR, Por1A, binds C4bp), and MS11 (rela-
tively SR, Por1B, binds C4bp). We observed that both
C4bp-binding strains showed a higher C4d/C4c ratio (4
for MS11 and 5.4 for FA19) than that observed with strain
F62 (1.17; Fig. 1). Thus, C4bp that binds to the bacterial
surface exhibits cofactor activity.
Defining Por as the Acceptor for C4bp
We next examined if Por1A was the acceptor molecule
for C4bp by replacing the Por1B of F62 (does not bind
C4bp) with the Por1A molecule of strain FA19 (binds286 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
C4bp) using plasmid pUNCH62 (40). Colony lifts of trans-
formants that resulted from homologous recombination
were screened using serotyping mAbs 2F12 and 9D2 (21)
that are specific for the NH2-terminal and central region of
FA19 Por, respectively (42, 54). Clones that reacted with
both mAbs were deemed to have acquired most of the
FA19 Por1A molecule in their F62 background. The pres-
ence of the entire FA19 Por molecule was confirmed by
DNA sequencing. One such isogenic mutant, designated
F62PorFA19, bound C4bp in a flow cytometry assay (Fig. 2,
left), and demonstrated 100% survival in 10% NHS (SR),
akin to the parent strain FA19.
Similarly, we used plasmid pUNCH61 (40) to replace
the Por molecule of F62 with MS11 Por. Transformants
were screened using mAbs 1F5 (specific for MS11 loop 1)
and 3C8 (specific for the central region of MS11, but not
F62, Por). Again, the presence of the entire MS11 Por
molecule was confirmed by DNA sequencing. The result-
ing strain (F62PorMS11) also bound C4bp (Fig 2, right), prov-
ing that the Por molecule functioned as a C4bp acceptor
on strain MS11. Unlike F62PorFA19, F62PorMS11 remained
fully SS to the bactericidal action of 10% NHS (SS). To
understand this apparent discrepancy between C4bp bind-
ing and phenotype, we analyzed other properties of this
strain (discussed below).
Defining Por Loops Required for C4bp Binding
C4bp Binding Region in Por1A. Transformation of F62
with plasmid pUNCH62 (40) produced clones with hybrid
Por1A/1B molecules that were recognized by mAb 9D2
(recognizes a central region of FA19 Por) but not mAb
2F12 (specific for FA19 loop 1), indicating that a recom-
bination had occurred between loop 1 and loop 5.
Two classes of hybrids were identified, one with F62loop1
FA19loop2–8, and the other with F62loop1–4FA19loop5–8 (Fig.
3). Neither class of hybrid bound C4bp, suggesting that the
loop 1 of FA19 Por1A was essential for C4bp binding.
We attempted to construct a hybrid Por in an F62 back-
ground that contained the NH2 terminus of FA19 Por
(loop 1), and the COOH terminus of F62, to test if such a
hybrid bound C4bp, thereby proving that loop 1 of FA19
contained the C4bp binding region exclusively. We were
unsuccessful having used the following strategies. The first
strategy we used was to transform F62 with pBUMC2 (see
Materials and Methods). A recombinational event that oc-
curred within the por gene would have resulted in a hybrid
containing the NH2 terminus of FA19 and the COOH ter-
Figure 2. Por1A of FA19 and Por1B of MS11 are the acceptor mole-
cules for C4bp. To demonstrate this for FA19 Por1A, we used
pUNCH62 (reference 40) to replace F62 Por1B (C4bp nonbinder) with
FA19 Por1A. The resultant strain, termed F62PorFA19, bound C4bp in a
flow cytometry assay when incubated with 10% NHS (left), indicating
that FA19 Por1A was an acceptor molecule for C4bp. Similarly, using
plasmid pUNCH61 (reference 40) we replaced F62 Por1B with MS11
Por1B, and observed that the isogenic mutant F62PorMS11 bound C4bp
(right), indicating that MS11 Por1B was an acceptor molecule for C4bp.
Figure 1. Demonstration of cofactor activity on gono-
coccal strains that bind C4bp. Strains F62, MS11, and
FA19 were incubated with 20% NHS for 30 min at 378C,
followed by detection of intact C4b fragments remaining
on the bacterial surface by flow cytometry. C4bp cofactor
activity would result in factor I–mediated cleavage of C4b
to C4c and C4d. C4d remains bound to the bacterial sur-
face, whereas the C4c fragment is released into solution.
Anti-C4d mAb recognizes both C4b as well as C4d,
whereas anti-C4c mAb recognizes only C4b bound to the
organism. Therefore, cofactor activity would result in decreased intact C4b detected on the organism (measured with the anti-C4c mAb), with a resultant
increase in the C4d/C4c ratio. Consistent with their ability to bind C4bp, both MS11 as well as FA19 show higher C4d/C4c ratios. geo mean flu, geo-
metric mean fluorescence.287 Ram et al.
minus of F62. Approximately 100 chloramphenicol-resis-
tant colonies (the result of two separate transformation ex-
periments) were screened using mAb 2F12 (specific for
FA19 Por loop 1), but none of the clones reacted with this
mAb. The second strategy was to construct a plasmid de-
rived from pUNCH62 that contained loop 1 from FA19
and loops 2–8 of a C4bp-nonbinding Por1B molecule by
cloning the BbsI-XbaI fragment of pBUMC1 into the cor-
responding region of pUNCH62. This plasmid coded for a
Por hybrid FA19loop1F62loop2–7MS11loop8. Attempts to trans-
form F62 with this plasmid also did not yield clones that
contained the desired hybrid. These results strongly sug-
gested that formation of this hybrid resulted in a lethal mu-
tation. Finally, we attempted to construct a more “physio-
logic” hybrid Por molecule containing FA19 loop 1 and
UU1 loop 2–8. Plasmid pBUMC3, containing the Por hy-
brid FA19loop1UU1loop2–8, was constructed and used to
transform F62, as well as UU1. However, none of z50
colonies from each transformation attempt reacted with the
FA19 loop 1 specific mAb 2F12, suggesting that the desired
hybrid had not been obtained. We also observed that rates
of transformation in all the above experiments were signifi-
cantly lower than with control plasmids pUNCH61 and
pUNCH62, again strongly suggesting that a hybrid con-
taining loop 1 from FA19 and loops 2 through 8 from ei-
ther F62 or UU1 were lethal to gonococci.
The results of the above experiments demonstrate that
FA19 loop 1 is required for C4bp binding. However, we
cannot conclude that the presence of this loop alone is suf-
ficient for C4bp binding.
C4bp Binding Region in Por1B. The C4bp binding re-
gion in MS11 Por1B was mapped using 12 strains contain-
ing F62/MS11 hybrid Por molecules, as shown in Fig. 4.
Transformation of strain F62 with plasmid pUNCH61 pro-
duced colonies that bound mAbs 3C8 (recognizes central
Figure 3. FA19 Por1A loop 1 is required for C4bp binding. Transfor-
mation of F62 with pUNCH62 (containing the FA19 por1A gene) re-
sulted in two classes of hybrid Por molecules, F62loop1FA19loop2–8 and
F62loop1–4FA19loop2–8. F62 (Por1B) sequence is shown by solid black bars,
and FA19 (Por1A) sequence by white bars. Neither class of hybrids
bound C4bp. Loop 1 of FA19 Por1A is indicated by the gray shaded box;
only parent strain FA19 that contains Por1A loop 1 binds C4bp, suggest-
ing that loop 1 of Por1A is required for C4bp binding.
Figure 4. MS11 Por1B loops
5 and 7 together participate in
forming a C4bp-binding region.
Transformation of F62 with
pUNCH61 (reference 40) re-
sulted in strains with hybrid Por
molecules F62loop1MS11loop2–8
and F62loop1–4MS11loop5–8. F62
sequence is indicated by black
bars; MS11 sequence is repre-
sented by hatched bars. Both hy-
brids bound C4bp, suggesting
that the C4bp binding region in
MS11 lay in a region encom-
passed by loops 5–8. The BbsI-
BsgI fragment of F62 was cloned
into pUNCH61 to obtain
pBUMC1 and this plasmid was
used to transform F62. This
yielded a gonococcal strain with
hybrid Por molecule MS11loop1
F62loop2–7MS11loop1–8, which did
not bind C4bp, thus eliminating
MS11 loop 8 as the C4bp bind-
ing loop. Using overlap exten-
sion PCR or site-directed mu-
tagenesis on pBUMC1, we
mutated loops 5, 6, or 7 either
individually or in combination
and then transformed F62. We
noted that only hybrid Por
molecules that contained both MS11 loop 5 and loop 7 bound C4bp. To further demonstrate the absolute requirement of MS11 loops 5 and 7, we mu-
tated MS11 loops 5, 6, and 7 individually in pUNCH61 to resemble the corresponding F62 loop, and then transformed F62. Mutations of loop 5
(MS11loop1–4F62loop5MS11loop6–8) and loop 7 (MS11loop1–6F62loop7MS11loop8) resulted in complete abrogation of C4bp binding, whereas mutating loop 6
(MS11loop1–5F62loop6MS11loop7–8) did not influence C4bp binding. Collectively, these data suggest that MS11 loops 5 and 7 together participate in forming
a C4bp-binding domain.288 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
region of MS11 Por; reference 42), but not mAb 1F5 (spe-
cific for MS11 loop 1; reference 42), indicating again that
recombination had occurred between loop 1 and loop 5.
Two classes of hybrids were identified, one with
F62loop1MS11loop2–8 and F62loop1–4MS11loop5–8. Both of these
hybrids bound C4bp, suggesting that the C4bp binding do-
main in Por1B lay in the COOH-terminal half of the mol-
ecule (Fig. 4).
We replaced the BbsI-BsgI fragment of pUNCH61 with
the corresponding BbsI-BsgI fragment from the F62 Por1B
molecule to obtain plasmid pBUMC1 that contained a hy-
brid Por sequence MS11loop1F62loop2–7MS11loop8 (Fig. 4).
Gonococcal colonies were screened using mAb 1F5 (spe-
cific for MS11 loop 1) to identify clones that were likely to
contain the constructed hybrid molecule. DNA sequencing
of the por gene confirmed that the gonococcal clones con-
tained the desired hybrid molecule. This hybrid did not
bind C4bp, thus narrowing down C4bp binding to a re-
gion encompassed by MS11 loops 5–7. Using overlap ex-
tension PCR or site-directed mutagenesis, we mutated the
exposed regions of loops 5, 6, and 7 individually in
pBUMC1 to reinsert MS11 sequence back into this region
of the F62 Por. Individual mutations of loops 5, 6, and 7
did not restore C4bp binding. We next studied the effects
of mutating the combinations of either loops 5 and 6, loops
6 and 7, or loops 5 and 7 together in pBUMC1 to simulate
MS11 loops. Only the presence of MS11 loop 5 and 7 si-
multaneously resulted in C4bp binding (as demonstrated by
the hybrid MS11loop1F62loop2–4MS11loop5F62loop6MS11loop7–8;
Fig. 4), suggesting that these two loops together partici-
pated in formation of a C4bp-binding domain (indicated by
the gray shaded boxes in Fig. 4).
To further demonstrate the necessity of MS11 Por loops
5 and 7, but not loop 6, for C4bp binding, we mutated
each of these loops individually in pUNCH61 (contains the
entire MS11 por sequence), to yield hybrid Por molecules
that differed from MS11 only at loops 5, 6, or 7, which
were mutated to duplicate these regions in F62. Substitu-
tion of loops 5 and 7 separately (hybrids MS11loop1–4F62loop5
MS11loop6–8 and MS11loop1–6F62loop7MS11loop8, respectively;
Fig. 4), but not loop 6 (hybrid MS11loop1–5F62loop6
MS11loop7–8), completely abrogated C4bp binding (Fig. 4).
Collectively, these data suggest that MS11 loops 5 and 7
participate in the formation of a C4bp binding domain.
Enhanced IgM Binding to F62PorMS11: Por Influences IgM 
Binding to Gonococci
Serum bactericidal testing revealed that F62PorMS11 was
fully susceptible (0% survival) to the killing action of 10%
NHS, despite its ability to bind C4bp. In contrast, hybrid
F62loop1MS11loop2–8 that differed from F62PorMS11 only at
Por loop 1 was fully resistant to 10% NHS. We compared
the Ig and complement (C3 and C5b-9) binding properties
of F62PorMS11 with F62loop1MS11loop2–8 and F62 to explain
the apparent paradox between the ability of F62PorMS11 to
bind C4bp and its SS phenotype. We observed that
F62PorMS11 bound two- and fourfold more IgM than parent
strain F62 and mutant strain F62loop1MS11loop2–8, respec-
tively (Fig. 5). The amount of C3 and C5b-9 bound to
F62PorMS11 was twofold more than that observed with
F62loop1MS11loop2–8, and fivefold less than that detected
on F62 (Fig. 5). IgG binding to the three strains was low
(geometric mean fluorescence ,10 for all strains), making
meaningful interstrain comparisons difficult. To demon-
strate that Ig was responsible for killing F62PorMS11, we
adsorbed NHS against glutaraldehyde-fixed bacteria
(F62PorMS11) at 48C to deplete NHS of bacteria-specific an-
tibody (41), which abrogated bactericidal activity against
this strain (100% survival observed). The addition of heat-
inactivated NHS to a final concentration of 10%, which
acted as an antibody source, restored 99% killing of
F62PorMS11. MS11 and F62loop1MS11loop2–8 showed 100%
survival (remained SR) under both bactericidal assay condi-
tions, and served as controls for this experiment. Similarly,
hybrid F62loop1–4MS11loop5–8, which was also found to be SS
despite binding C4bp, bound levels of IgM that were simi-
Figure 5. Enhanced IgM binding to F62PorMS11: Por influences IgM
binding to gonococci. Despite the ability of F62PorMS11 to bind C4bp (see
Fig. 2), the resulting transformant possessed the SS phenotype on bacteri-
cidal testing (100% killing in 10% NHS at 30 min). To determine the
mechanism of serum sensitivity, we studied the binding of IgM, C3,
C5b-9, and C4bp to F62PorMS11 (gray shaded areas) in comparison with
F62 (dotted lines) and F62loop1MS11loop2–8 (solid lines). In contrast to
F62PorMS11, F62loop1MS11loop2–8 was fully SR (100% survival in 10% NHS
at 30 min), and differed from the former only at Por loop 1. F62PorMS11
bound two- and fourfold more IgM than F62 and F62loop1MS11loop2–8, re-
spectively. Levels of C3 and C5b-9 binding to F62PorMS11 were intermedi-
ate compared with the two other strains. C4bp binding to F62PorMS11 and
F62loop1MS11loop2–8 were identical.289 Ram et al.
lar to those observed with F62PorMS11. These data provide
evidence that the Por molecule, in addition to determining
C4bp binding, may also dictate levels of IgM binding to
the gonococcal surface, and that the two factors may inter-
act to determine bacterial killing.
Characterization of the bonds between C4bp and Por.
The effects of ionic strength and the influence of two
known ligands of C4bp (C4b and heparin) on C4bp–Por
interactions were studied. C4b, when added in a 60-fold
molar excess of C4bp, decreased binding of C4bp to MS11
by 50% (Fig. 6 A). In the presence of 125 units of heparin
(Fig. 6 B) or 575 mM NaCl (Fig. 6 C), binding of C4bp to
MS11 was decreased by .90% and z85%, respectively.
None of these three conditions influenced the binding of
C4bp to Por1A strain FA19. Based on these observations, it
may be concluded that the C4bp–Por1B bond is ionic in
nature, and that the binding site for Por1B in C4bp may
reside at or very near binding sites in C4bp for heparin and
C4b, which has been mapped to the interface between
SCRs 1 and 2 (34). This region also overlaps the binding
site for streptococcal M proteins (55). In contrast, the
Por1A–C4bp interaction could be hydrophobic, and is not
influenced by ionic strength of buffers or heparin.
C4bp SCR1 contains Por1A as well as Por1B binding
sites. We determined that the binding site for gonococcal
Por1A as well as Por1B resided in the a-chain of C4bp be-
cause recombinant polymeric human C4bp (rC4bp) that
lacked the b-chain bound to FA19 as well as MS11 using
flow cytometry. Native C4bp purified from human serum
(containing the b-chain) bound to these two strains with
similar fluorescent intensity as rC4bp (data not shown).
Neither type of C4bp bound to strain F62. To determine
the specific SCR(s) of C4bp that bound gonococci, we
used rC4bp molecules expressed in human kidney cell line
293 that lacked individual a-chain SCRs and studied their
binding to strains FA19 and MS11. rC4bp mutant mole-
cule that lacked SCR1 bound neither FA19 or MS11, sug-
gesting that SCR1 was required for binding to both gono-
coccal Por types (Fig. 7 A). Deletion of other domains
individually had no significant impact on C4bp binding to
gonococci. Further proof that SCR1 bound to both Por1A
(strain FA19) and Por1B (strain MS11) was evidenced by
showing that five mAbs directed against the NH2-terminal
end of the a-chain of C4bp (mAb 70, mAb 92, mAb 96,
mAb 102, and mAb 104; reference 51) each were able to
completely inhibit C4bp binding to both strains (as an ex-
ample, mAb 104 inhibition of C4bp binding shown in Fig.
7 B). mAb 67, directed against C4bp a-chain SCR4 (51),
did not influence C4bp binding to either strain and served
as a control for this experiment (Fig. 7 B).
To determine if the organization of the heptameric
a-chain structure of the C4bp molecule was required for
C4bp binding to Por, we studied binding of 5 mg of re-
combinant monomeric a-chain of C4bp that contained all
eight a-chain SCRs, to strains FA19 and MS11 in a flow
cytometry assay. The monomeric molecule did not bind to
either Por, indicating a requirement for the polymeric form
of C4bp a-chains to bind gonococcal Por (data not
shown). Both mAb 67 as well as polyclonal anti-C4bp
(Biodesign), which were used as detection Abs in flow cy-
tometry, were capable of binding either monomeric or
polymeric C4bp (data not shown).
Figure 6. Characterization of Por–C4bp bonds.
The influence of C4b, heparin and high-ionic
strength on Por-C4bp binding was studied by flow
cytometry. C4b, when added to C4bp in a 60-fold
molar excess, inhibited C4bp binding to MS11
(Por1B) by 40% (A). 125 units of heparin com-
pletely inhibited C4bp binding to MS11 (B), and
575 mM NaCl reduced C4bp binding to MS11 by
.80% (C). None of the above conditions influ-
enced C4bp binding to FA19 (Por1A). To mini-
mize bacterial lysis in these experiments, organisms
were first fixed with 1% paraformaldehyde. Fixing
gonococci before incubation with C4bp did not al-
ter C4bp binding properties.290 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
Abrogating C4bp binding to gonococci results in com-
plete bacterial killing. We have shown that C4bp that binds
directly to the bacterial surface exhibits cofactor activity
(see above). The ability to kill SR gonococci by selectively
inhibiting C4bp binding would provide more definitive
proof of the biological importance of this molecule. We
prepared fAb fragments from mAb 104, and demonstrated
that fAb 104, when added to NHS, completely inhibited
C4bp binding to FA19 as well as to MS11 in a flow cytom-
etry assay (Fig. 8 A). fAb 67 was used as a control, and did
not influence C4bp binding to gonococci (not shown). We
confirmed that fAb 67 retained 60% of the ability of mAb
67 to bind C4bp in ELISA (data not shown). Abrogating
C4bp binding with fAb 104 resulted in a decreased C4d/
C4c ratio, as well as enhanced C5b-9 insertion in the bac-
terial membrane (Table V), demonstrating that classical
pathway regulatory activity was lost when C4bp binding to
FA19 and MS11 was inhibited. We also performed a bacte-
ricidal assay including fAb 104 in the reaction mixture
(molar ratio of fAb 104 to C4bp in the reaction mixture
z70) to divert C4bp away from these bacterial surfaces.
We observed complete killing of strain FA19, and .80%
killing of MS11 at t 5 30 min (Fig. 8 B). fAb 67, used as a
control, showed no effect. Kinetics of bacterial killing
showed an almost linear and steady decrease in bacterial vi-
ability over time, with almost complete killing observed at
30 min (Fig. 8 C) when C4bp binding was abrogated. The
importance of C4bp in contributing to serum resistance of
FA19 and MS11 can be gauged from the fact that both
strains resist bactericidal activity of up to 33% NHS (24);
FA19 resists killing of up to 66% NHS.
Discussion
Complement is present in cervical secretions (3), and
evasion of complement-mediated killing is vital for survival
of gonococci. N. gonorrhoeae have evolved intricate mecha-
nisms to evade complement. All gonococcal strains initially
recovered from the human genital tract are resistant to the
bactericidal action of NHS; strains that lose this property
upon serial subculture (56) are termed unstably serum resis-
tant, and this phenotype is facilitated by binding of factor H
to sialic acid attached to LOS (12).
Strains that remain resistant after subculture are termed
SR strains. Prior work in our laboratory has also defined
factor H binding to the loop 5 of Por1A strains as a proba-
ble mechanism of stable serum resistance (24). In these
studies, we have shown C4bp binding to Por1A as an addi-
tional mechanism whereby Por1A strains can evade com-
plement. However, Por1B isolates form a significant pro-
portion gonococcal isolates worldwide (57–59). Por1B
strains are generally non- or weak binders of factor H, and
must therefore evade complement by other mechanisms.
This study defines C4bp binding to Por1B as an important
mechanism of stable serum resistance in gonococci that be-
long to this serogroup.
We have shown that a strong correlation between C4bp
binding and stable serum resistance in gonococci. None of
the serum sensitive strains recovered from persons with
gonococcal disease that we tested were C4bp binders (Ta-
ble I). However, during the course of our studies, we ob-
served that introduction of the entire MS11 Por1B-9 into
an F62 background (F62PorMS11) resulted in C4bp binding
as expected (Fig. 1), but unexpectedly did not convert the
transformant to an SS phenotype. However, hybrid Por
Figure 7. C4bp SCR 1 contains
both Por1A as well as Por1B binding
regions. (A) Mapping of Por binding
sites in C4bp. Binding of recombi-
nant C4bp (rC4bp) and seven rC4bp
mutant molecules lacking individual SCRs to FA19 (Por1A) and MS11
(Por1B) were studied using flow cytometry. 108 organisms were incu-
bated with 2.5 mg of each rC4bp molecule, followed by detection with
sheep polyclonal anti–human C4bp and disclosed with anti–sheep IgG-
FITC. All rC4bp molecules that contained SCR 1 bound both FA19 as
well as MS11; only the mutant that lacked SCR 1 (rC4bp DSCR1) did
not bind either strain. Because artifactually lower fluorescence (threefold
less binding compared with rC4bp) was observed when rC4bp DSCR6
was detected with the polyclonal anti-C4bp Ab, we used anti-C4bp mAb
(Quidel Corp.) and mAb 67 (specific for SCR 4) to detect rC4bp
DSCR6 bound to both strains. Compared with rC4bp, rC4bp DSCR6
bound with similar fluorescence intensities, when either mAb was used as
a probe. Binding of rC4bp DSCR6 to both strains using the Quidel
Corp. mAb is shown here (indicated by the asterisk). rC4bp DSCR1 did
not bind to either strains when mAb 67 or the Quidel Corp. anti-C4bp
mAb was used as the detection Ab. (B) Anti-C4bp SCR1 mAb blocks
C4bp binding to gonococci. Further evidence that SCR 1 contains
Por1A and Por1B binding regions was provided because mAb 104 that is
specific for C4bp SCR 1 completely inhibits binding of C4bp to both
FA19 (Por1A) as well as MS11 (Por1B; solid lines); control mAb 67 (spe-
cific for the irrelevant C4bp SCR 4) did not influence C4bp binding to
either strain (gray shaded area) when compared with binding of pure
C4bp alone (dashed lines).291 Ram et al.
molecule F62loop1MS11loop2–8 moved into the same F62
background also bound the same amount of C4bp, but was
fully SR. Almost fourfold higher levels of IgM bound to
F62PorMS11 compared with F62loop1MS11loop2–8 (Fig. 5).
These data provide evidence that, in addition to binding
C4bp, the Por molecule may also dictate levels of IgM
binding to surface targets, most likely LOS (15, 60, 61). In
addition, levels of C3 and C5b-9 binding to F62PorMS11
were greater than for F62loop1MS11loop2–8, but less so than
for F62 (Fig. 5). These data suggest that C4bp bound to
F62PorMS11 was indeed capable of regulating complement
downward, but this was still not sufficient to overcome the
initial overwhelming complement activation by IgM.
Thus, in the face of high levels of IgM and kinetically over-
whelming complement activation, C4bp binding alone
may not be sufficient for serum resistance.
We did not succeed in constructing hybrid Por mole-
cules that contained loop 1 of FA19 loops 2 through 8 of
F62 or UU1. The apparent transformation rates with plas-
mids that contained these Por hybrid sequences were sig-
nificantly lower than observed with pUNCH61, suggesting
that recombination events that might result in generating
this Por hybrid were deleterious or possibly lethal. There-
fore, we can conclude that the NH2-terminal Por1A loop
is required for C4bp binding, but it may not necessarily
contain the entire C4bp binding region.
Using rC4bp mutant molecules as well as anti-C4bp
mAbs, we have shown that the NH2-terminal SCR of
C4bp contains both Por1A as well as Por1B binding re-
gions (Fig. 7). Por1A and Por1B binding regions in SCR 1
of C4bp may differ because Por1B–C4bp, but not Por1A–
C4bp, interactions can be inhibited by C4b, heparin, as
well as high ionic strength (Fig. 6). Akin to Por1B–C4bp
interactions, the bond between streptococcal M protein and
C4bp appears to occur in close proximity to the C4b bind-
ing region in C4bp. However, the M protein–C4bp bond,
unlike the entirely electrostatic C4bp–C4b bond, is gov-
erned by additional noncovalent forces (55). We have
shown that loops 5 and 7 of Por1B loop in strain MS11 are
both required for C4bp binding (Fig. 4). Both of these
loops together may participate in forming a negatively
charged patch that is required for Por1B–C4bp interactions.
The overall charge of the exposed regions of loops 5 and 7
together is 23, while F62 (a C4bp nonbinder) loops 5 and
7 together possess a net negative charge of 21.5 (Table II).
Figure 8. Functional effects of blocking C4bp binding to gonococci.
(A) fAb 104 inhibits C4bp binding to gonococci. 20 mg of fAb fragments
generated from mAb 104, when added to 10% NHS, inhibited C4bp
binding to FA19 and MS11 equally (gray shaded area). C4bp binding in
the presence of NHS alone is shown by the solid line. (B) Diverting C4bp
from the bacterial surface converts SR gonococci to an SS phenotype. A
serum bactericidal assay was performed to assess the functional effects of
inhibiting the binding of C4bp binding to the bacteria. FA19 and MS11
were incubated either with 10% NHS alone, 10% NHS plus 25 mg fAb
104, or 10% NHS plus 25 mg fAb 67 (negative control) for 30 min at
378C. fAb 104 abrogated C4bp binding to the bacterial surface resulting
in 100% killing of FA19 and 80% killing of MS11. NHS alone or NHS
with (irrelevant) fAb 67 resulted in no significant killing of either strain.
(C) Kinetics of bacterial killing by an unimpeded classical pathway. Abro-
gation of C4bp binding to the bacterial surface resulted in slow, sustained
bacterial killing, with an almost linear decrease in bacterial viability over
time of both FA19 (solid line) and MS11 (dotted line).
Table V. Inhibition of C4bp Binding to Gonococci Results in 
Complement Deposition on the Bacterial Surface
Strain
Opsonization
condition C4c* C4d* C4d/C4c C5b-9*
FA19 NHS 2.9 9.3 3.2 4.0
NHS plus fAb 104 5.7 6.2 1.1 25.3
MS11 NHS 2.6 6.9 2.7 4.4
NHS plus fAb 104 4.8 4.4 0.9 30.1
The effects of inhibiting C4bp binding in 20% NHS to FA19 and MS11
on the resultant binding of C4c, C4d, and C5b-9 to FA19 and MS11
were examined. Diminished binding of C4bp to the bacteria resulted in
an increased C4d/C4c ratio, and increased C5b-9 binding to both
strains.
*Binding expressed as geometric mean fluorescence.292 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
C4bp function was also shown to be important because
C4bp binding to the bacterial surface was abrogated using
fAb 104. This resulted in complete killing of strain FA19,
and .80% killing of MS11, both in the presence of only
10% NHS (Fig. 8 B). The pivotal role of C4bp in mediat-
ing stable serum resistance of these two strains can be
gauged by the fact that both strains are otherwise fully resis-
tant to 33% NHS (24).
The relatively slow, but sustained killing by unimpeded
activation of the classical pathway is evident from the ki-
netics of bacterial killing when C4bp binding to the bacte-
rial surface was inhibited by fAb 104 (Fig. 8 C). In contrast,
abrogating factor H binding to strain FA19 results in almost
instantaneous, although incomplete, killing (24). These ob-
servations indicate that both pathways together are critical
for efficient and complete bacterial killing. The relatively
slow killing by the classical pathway (alone) can be ex-
plained because C1s, the enzyme that generates the classical
pathway convertases, remains bound to the organism sur-
face and is therefore not available to cycle and again act on
its substrate. In contrast, factor D, the enzyme that gener-
ates the alternative pathway convertases, is liberated after it
acts on its substrate, C3bB, thus enabling recycling and effi-
cient amplification of C3b deposition. Notably, MS11,
which did not bind factor H, was also killed slowly, per-
haps unexpectedly if rapid alternative pathway recruitment
and efficient killing of this strain were to be expected when
C4bp binding to the surface of MS11 was blocked. In an
effort to explain these findings, we analyzed and compared
total C3, C3b, iC3b, and factor Bb on strains MS11 and
24-1 (the latter is an SS Por1B strain, and does not bind ei-
ther factor H or C4bp; reference 12). After 10 min op-
sonization with 10% NHS, we observed that MS11 bound
45% less C3 than 24-1, and almost all the C3b on MS11
was converted to iC3b, whereas C3b on 24-1 remained
unprocessed. MS11 bound fivefold less factor Bb than 24-1.
These data suggest regulation of the alternative pathway
on the surface of MS11 despite its inability to bind pure
factor H. A possible explanation for this phenomenon
could include the ability of MS11 to bind factor H–like
protein 1 (FHL-1), which is an alternatively spliced form of
full-length factor H found in human serum (62, 63), and
has been shown to bind M proteins of group A streptococ-
cus and exert cofactor activity (64, 65). Other possibilities
include decreased affinity of factor B for C3b on MS11, or
endogenous factor H-like activity of the organism; the lat-
ter has been reported with Epstein-Barr virus (66), and
merits further investigation.
Por is antigenic during natural infection (67–69) and cer-
tain evidence suggests that women with gonococcal PID
and female commercial sex workers with a history of mul-
tiple gonococcal infections may be protected against re-
peated infection with the same serovar (70). However,
other studies, involving predominantly male populations,
suggest that serovar-specific protection may not be a fea-
ture of gonococcal disease (71, 72). Gonococcal Por under-
goes antigenic variation in vivo over time as shown by di-
versity of serovars recognized in a sexual network (70, 73).
Subtle differences in Por sequence can occur even among
isolates belonging to the same serovar (74). An interesting
feature of nucleotide polymorphisms in the por gene is that
maximum rates of nucleotide diversity occur in the puta-
tive exposed portion of Por1A loop 1 and Por1B loop 5
(75); both of these regions are critical for C4bp binding.
The ability of the Por molecule to undergo sequence alter-
ations potentially could also abrogate binding of bacteri-
cidal antibodies (76, 77), in the face of retention (and per-
haps an increase) in the capacity to bind complement
regulators such as factor H and C4bp. This is especially
likely in the case of Por1B strains, where the C4bp binding
domain is formed by two noncontiguous loops and is
charge dependent.
In conclusion, gonococci have several mechanisms that
act cooperatively to mediate serum resistance. Factor H
binds to sialic acid on LOS and mediates unstable serum re-
sistance. Several nonsialylated gonococci can use their Por
molecule to bind regulatory molecules to evade comple-
ment-mediated killing. Por1A strains bind factor H
through loop 5 and C4bp possibly through loop 1, and the
greater negative charge of the exposed regions of loops 5
and 7 of certain Por1B strains enable them to bind C4bp.
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